With recent leadership shakeups, many are wondering how FDA will change its approach to regulating DTC pharma advertisements.
Dan Troy
Advertisement
Dan Troy is a former lead counsel for FDA.
Articles by Dan Troy
Former chief counsel for FDA Dan Troy explains why there is no firm timeline for regulatory reform or update at FDA for DTC pharma advertisements.
Dan Troy, former FDA chief counsel, explains limits on what regulations FDA can put on DTC advertisements.
Former FDA chief counsel Dan Troy discusses the motivation behind potential DTC pharma ad bans.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Pharma M&A Roundup: Servier Acquiring Edgewise Therapeutics' Muscular Dystrophy Business, Hanmi Enters Licensing Agreement with Eli Lilly, Avenzo Enters Merger Agreement with Rallybio
2
CVS Restores Coverage of Lilly’s Zepbound, Adds Oral Obesity Drug Foundayo
3
FDA Approves Xocova as First Oral Post-Exposure Covid-19 Prevention Therapy
4
Why Breakthrough Cell and Gene Therapies Still Fail at the Finish Line
5